BreezeBio Raises $60M in Series B Funding for Genetic Medicines Platform

In 2016, in Silicon Valley, Kunwoo Ryan Lee, Ph.D. started with a question most people were too polite to ask out loud. If mRNA and DNA are the message, why is delivery still the problem? So he built the envelope. Polymer based nanoparticles engineered to carry genetic cargo exactly where it needs to go. No viral theatrics. No lipid drama. Just precision. That company was GenEdit. Today, it answers to BreezeBio.

This week BreezeBio secured $60M in Series B financing to advance its internal pipeline of precision genetic medicines. Led by Yuanta Investment and DSC Investment, with participation from SV Investment, Kiwoom Investment, STIC Ventures, Top Harvest Capital and returning investors including DAYLI Partners, Pathway Investment, Loftyrock Investment, Korea Investment Partners, WOORI Venture Partners, KDB Silicon Valley and ACVC Partners. Vincent Jeong of Yuanta Investment did not mince words about the platform’s potential. Smart capital rarely does.

That brings clearly documented institutional funding to at least $84M when you add the $24M Series A1 announced in January 2024. Back then, Eli Lilly, Sequoia Capital and a syndicate of global investors leaned in. Not for vibes. For validation. For data. For a platform called NanoGalaxy that treats delivery like a discipline, not an afterthought.

NanoGalaxy is a proprietary, non viral, non lipid hydrophilic nanoparticle system designed for tissue selectivity, payload flexibility and re dosing potential. It has demonstrated delivery of genetic material to immune cells and selected tissues in the heart, lungs and central nervous system. That is not marketing copy. That is architecture. And architecture is what determines whether a genetic therapy is a headline or a habit.

BreezeBio is no longer just a platform company. The rebrand signals intent. Internal programs. Real shots on goal. The lead candidate, BRZ 101, is designed to restore immune tolerance in type 1 diabetes and is advancing through IND enabling studies. Precision is not a buzzword here. It is the difference between suppressing an immune system and teaching it.

The company is also deep into a multiyear collaboration with Genentech to develop nanoparticles for autoimmune disease. When Roche’s house brand shows up, it is because the science survived the room.

Kunwoo Ryan Lee, Ph.D. built the delivery engine. J. Rodrigo Mora, M.D., Ph.D., appointed as CSO of GenEdit in 2024, expanded the NanoGalaxy platform into immunology. The baton has been passed from promise to program.